Volume | 605,625 |
|
|||||
News | (1) | ||||||
Day High | 21.25 | Low High |
|||||
Day Low | 20.26 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kura Oncology Inc | KURA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.55 | 20.26 | 21.25 | 20.63 | 20.59 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,470 | 605,625 | $ 20.49 | $ 12,407,207 | - | 7.41 - 24.17 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:30:08 | 1 | $ 20.74 | USD |
Kura Oncology Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.57B | 76.14M | - | 0 | -152.63M | -2.00 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kura Oncology News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KURA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.20 | 21.25 | 18.95 | 20.05 | 599,753 | 1.43 | 7.45% |
1 Month | 20.09 | 21.25 | 16.79 | 18.99 | 834,362 | 0.54 | 2.69% |
3 Months | 20.49 | 24.17 | 16.79 | 20.64 | 925,540 | 0.14 | 0.68% |
6 Months | 8.76 | 24.17 | 8.17 | 17.17 | 1,234,286 | 11.87 | 135.50% |
1 Year | 10.25 | 24.17 | 7.41 | 14.58 | 995,358 | 10.38 | 101.27% |
3 Years | 27.33 | 27.54 | 7.41 | 15.11 | 836,852 | -6.70 | -24.52% |
5 Years | 15.17 | 42.82 | 6.34 | 17.65 | 709,050 | 5.46 | 35.99% |
Kura Oncology Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. |